Celldex Therapeutics Keeps Up Its Penny-Pinching and Pipeline Progress
Celldex Therapeutics (NASDAQ: CLDX) has two primary goals in 2019. First, the biotech wants to advance its pipeline candidates. Second, it wants to stretch out its cash as much as possible. Celldex did pretty well on both counts when it reported its first-quarter results in May.
The company provided an update on its second-quarter progress after the market closed on Wednesday. Here are the highlights from Celldex's latest quarterly report.
Image source: Getty Images.
Quelle Fool.com
